Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer

To develop a combinatorial biomarker strategy with increased specificity for immune checkpoint blockade unresponsiveness in NSCLC, researchers performed a comprehensive analysis of 254 NSCLC patients treated with PD-(L)1 blockade monotherapy.